Spots Global Cancer Trial Database for met mutation
Every month we try and update this database with for met mutation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Merestinib In Non-Small Cell Lung Cancer And Solid Tumors | NCT02920996 | Carcinoma, Non-... Solid Tumor | Merestinib | 18 Years - | Dana-Farber Cancer Institute | |
Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation | NCT04427072 | Carcinoma, Non-... | Capmatinib Docetaxel | 18 Years - | Novartis | |
Merestinib In Non-Small Cell Lung Cancer And Solid Tumors | NCT02920996 | Carcinoma, Non-... Solid Tumor | Merestinib | 18 Years - | Dana-Farber Cancer Institute | |
Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation | NCT04427072 | Carcinoma, Non-... | Capmatinib Docetaxel | 18 Years - | Novartis | |
Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation | NCT04427072 | Carcinoma, Non-... | Capmatinib Docetaxel | 18 Years - | Novartis | |
Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation | NCT04677595 | Non-Small Cell ... | Capmatinib | 18 Years - | Novartis | |
Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation | NCT04677595 | Non-Small Cell ... | Capmatinib | 18 Years - | Novartis | |
Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations | NCT04323436 | Carcinoma, Non-... | Spartalizumab Capmatinib spartalizumab p... | 18 Years - | Novartis | |
Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies | NCT05370469 | Lung Cancer EGFR Gene Mutat... EGFR ALK Gene Mutati... RET Gene Mutati... MET Gene Mutati... KRAS Mutation-R... BRAF ROS1 Gene Mutat... | Sensus Smartwat... RX Cap Fitbit Sense Surveys | 18 Years - | University of Virginia | |
Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations | NCT04323436 | Carcinoma, Non-... | Spartalizumab Capmatinib spartalizumab p... | 18 Years - | Novartis |